BAMS
ICPT

Bellevue Asset Management (Switzerland)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$2.02M Buy
13,500
+4,800
+55% +$813K 0.31% 85
2015
Q3 		$1.44M Buy
8,700
+1,200
+16% +$264K 0.24% 96
2015
Q2 		$1.81M Buy
7,500
+1,000
+15% +$266K 0.25% 89
2015
Q1 		$1.83M Buy
+6,500
New +$1.41M 0.26% 91

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s ICPT Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 55% in Q4 2015, buying an estimated $813K and bringing the position to 13,500 shares worth $2.02M. The position accounts for 0.31% of the portfolio, ranked #85.

Bellevue Asset Management (Switzerland) first reported a position in ICPT in Q1 2015 and has held it in 4 quarters since. 172 funds tracked by Wall St. Rank hold ICPT as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 13,500 shares of Intercept Pharmaceuticals, Inc. worth $2.02M as of Q4 2015.
  • Bellevue Asset Management (Switzerland) bought 4,800 Intercept Pharmaceuticals, Inc. shares in Q4 2015, an estimated $813K.
  • Intercept Pharmaceuticals, Inc. made up 0.31% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #85 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and has held it in 4 quarters since.
  • 172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.